Medication info

Megavalartan Tablet 160 mg (Valsartan)

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Valsartan›160mg / 1 tablet
Manufacturer / importer
L&C Bio Co., Ltd.
Appearance
Oval film-coated tablet with an orange color tinged with gray
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 202002082 · Approved 2020.03.25

This product's status changed to Approval withdrawn on 2024.09.04. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: Regardless of sex or race, valsartan 80 mg orally once daily is recommended. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be coadministered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years or older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with reduced intravascular volume: In patients with reduced intravascular volume (e.g., patients receiving high-dose diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. If a diuretic is coadministered, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine per dose twice daily, followed over several weeks by dose increases, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal impairment occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, coadministration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, as there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this medicine to these patients. 5. Patients with hepatic impairment: The daily dose of this medicine should preferably not exceed 80 mg in patients with mild to moderate hepatic impairment. If a dose of 80 mg or more per day is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
1) Children: The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age. 6. Children: The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
L&C Bio Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular failure
  • left ventricular systolic dysfunction
View approved original text

This drug is used for essential hypertension, heart failure, and reduction of mortality risk after myocardial infarction. It is particularly effective in steadily controlling blood pressure in patients with essential hypertension and is helpful in cases where ACE inhibitors cannot be used in heart failure patients. Additionally, it helps reduce the mortality risk in stable patients post-myocardial infarction with left ventricular dysfunction. This drug is used to improve these conditions.

How to take

Adult dose

(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: Regardless of sex or race, valsartan 80 mg orally once daily is recommended. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be coadministered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years or older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with reduced intravascular volume: In patients with reduced intravascular volume (e.g., patients receiving high-dose diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. If a diuretic is coadministered, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine per dose twice daily, followed over several weeks by dose increases, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal impairment occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, coadministration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, as there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this medicine to these patients. 5. Patients with hepatic impairment: The daily dose of this medicine should preferably not exceed 80 mg in patients with mild to moderate hepatic impairment. If a dose of 80 mg or more per day is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

1) Children: The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age. 6. Children: The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.

Precautions

This drug can cause severe harm to the fetus, especially during the second and third trimesters of pregnancy, so it must be discontinued immediately if pregnancy is confirmed. Women who are pregnant, may become pregnant, or are nursing should not take this drug. It is also unsafe for patients with severe liver dysfunction, liver cirrhosis, or bile duct obstruction. Patients with hereditary angioedema or a history of angioedema should not take this drug. Patients with very poor kidney function, primary hyperaldosteronism, or diabetes patients with moderate to high decline in kidney function should not take this drug. Elderly patients, or those with elevated potassium or slightly reduced liver function, should be cautious while taking this drug and may require dosage adjustments. Patients with heart valve disease or hypertrophic cardiomyopathy, and patients with ischemic heart disease or cerebrovascular disease are also at risk of dangerously low blood pressure while taking this drug. When starting this medication, blood pressure may drop suddenly, so those on diuretics or who are dehydrated should start at a low dose and gradually increase it. Patients with renal artery stenosis may experience worsening kidney function while taking this medication, thus requiring special monitoring. Patients post-heart failure or myocardial infarction should regularly verify changes in kidney function, and concurrent use with beta-blockers or ACE inhibitors is not recommended. This drug may rarely cause side effects such as headache, dizziness, cough, diarrhea, and fatigue, and in rare instances, severe allergic reactions or angioedema, along with kidney function impairment. Blood tests may show decreased red blood cell counts or elevated liver function levels, so assessments are advisable when needed. This drug may interact with other antihypertensive medications or various drugs, so be sure to inform healthcare professionals of any medications currently being taken. Especially, taking potassium-sparing diuretics or potassium supplements together with this drug can dangerously elevate blood potassium levels. Women who are pregnant or nursing should not take this drug, and nursing should ideally be discontinued. Safety and efficacy have not been established for children under 18 years of age. Elderly individuals should be cautious for the risk of stroke due to blood pressure lowering and should start at a low dose while being monitored closely. In case of overdose, severe hypotension and decreased consciousness may occur, requiring immediate emergency treatment. This drug should be kept out of reach of children and not transferred to other containers.

Side effects

  • Headache
  • dizziness
  • viral infection
  • upper respiratory tract infection
  • cough
  • diarrhea
  • fatigue
  • rhinitis
  • sinusitis
  • abdominal pain
Show 51 more
  • stomach ache
  • nausea
  • pharyngitis
  • arthralgia
  • hypotension
  • orthostatic dizziness
  • orthostatic hypotension
  • kidney function impairment
  • hyperkalemia
  • angioedema
  • heart failure
  • vascular edema
  • erythema
  • pruritus
  • serum sickness
  • vasculitis
  • syncope
  • nosebleed
  • hepatitis
  • interstitial pneumonia
  • hypoglycemia
  • shock
  • loss of consciousness
  • rhabdomyolysis
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • bullous dermatitis
  • reduced red blood cell volume
  • decreased hemoglobin
  • neutropenia
  • edema
  • asthenia
  • insomnia
  • decreased libido
  • drowsiness
  • atrial fibrillation
  • vomiting
  • constipation
  • thirst
  • decreased appetite
  • lethargy
  • dyspepsia
  • anemia
  • tinnitus
  • anxiety
  • decreased motor function
  • confusion
  • chest pain
  • rash
  • myalgia

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a sealed container to avoid exposure to air or moisture and kept in a cool place below 30 degrees Celsius. This will help to maintain the drug's effectiveness for a longer period.

Appearance and packaging

Appearance

Oval film-coated tablet with an orange color tinged with gray

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.